
Home
Chapter Home
Jobs
Conferences
Fellowships
Books
Advertisement
Stains
p63
Reviewer: Nat Pernick, M.D. (see Reviewers
page)
Revised: 16 April 2012, last major update April 2012
Copyright: (c) 2002-2012, PathologyOutlines.com, Inc.
Definition
=========================================================================
● Member of p53 gene family at 3q27-29, but does not appear to be a tumor suppressor gene
● Myoepithelial marker; others are smooth muscle myosin heavy chains, calponin, p75, P-cadherin, basal cytokeratins (CK 5/6), maspin, and CD10 (Arch Pathol Lab Med 2011;135:422)
Pathophysiology
=========================================================================
● Encodes at least 6 different proteins with different biologic functions
● Appears to regulate growth and development of epithelial organs (J Biomed Biotechnol 2011;2011:864904),
as germline mutations cause ectrodactyly (missing or irregular fingers
or toes), ectodermal dysplasia and facial clefts syndrome, also called
limb mammary syndrome (hypoplasia / aplasia of mammary glands and
nipple)
● May be molecular switch for initiation of “epithelial stratification program”
● Regulates human keratinocyte proliferation (J Biol Chem 2012;287:5627), olfactory stem cell self-renewal and differentiation (Neuron 2011;72:748)
● Gene and protein expression may not correlate due to presence of isoforms and post-translation modification
● Main isoforms are TAp63 and deltaNp63
● TAp63 ("full length" p63) activates p53 target genes, but deltaNp63
inhibits transcription activation of p53 gene and transactivating
isoforms
● TAp63 is highly expressed in most benign tumors; negative / weak in
most carcinomas, but deltaNp63 is negative / weak in most benign tumors
and highly expressed in adenoid cystic, mucoepidermoid and myoepithelial
carcinomas (Hum Pathol 2005;36:821)
Interpretation
=========================================================================
● Typically a nuclear stain
● Cytoplasmic staining of Z-bands of benign and malignant skeletal muscle tumors (Mod Pathol 2011;24:1320)
Uses by pathologists
=========================================================================
● Rule out invasion in breast tumors by determining presence of myoepithelial cells (Am J Surg Pathol 2001;25:1054)
● Confirm diagnosis of prostatic adenocarcinoma (p63-, Am J Surg Pathol 2002;26:1161); triple stain with P504S (AMACR) and CK903 (HMWCK) is recommended (Am J Clin Pathol 2007;127:248); note that partial atrophy may have similar staining as carcinoma (Am J Surg Pathol 2008;32:851); prostate cancer rarely expresses diffuse p63 staining in a nonbasal cell distribution (Am J Surg Pathol 2008;32:461)
● Rule out invasion in salivary gland tumors by determining presence of myoepithelial cells
● Determine squamous differentiation (p63+) for H&E or cytology cases as part of panel (Am J Clin Pathol 2011;136:81), but p63 rarely stains adenocarcinoma (Am J Surg Pathol 2011;35:15)
● Differentiate cutaneous sweat gland / adnexal carcinoma (p63+) from
metastatic breast / adenocarcinoma to skin (p63-) as part of panel (Arch Pathol Lab Med 2011;135:975, Mod Pathol 2010;23:713)
● Differentiate olfactory neuroblastoma (p63-/calretinin+) from other
small round blue cell tumors of sinonasal tract (often p63+/calretinin-,
Am J Surg Pathol 2011;35:1786)
● Differentiate renal collecting duct carcinoma (p63-/PAX8+) from upper tract urothelial carcinoma (opposite, Am J Surg Pathol 2010;34:965)
● Differentiate high-grade prostate cancer (p63-) from infiltrating high-grade urothelial cancer (often p63+) as part of panel (Am J Surg Pathol 2007;31:1246)
● Associated with poorer prognosis for Merkel cell carcinoma (Mod Pathol 2011;24:1451)
● Identifies "false" lymphatic invasion (tumor cells surrounded by D2-40+/p63- ducts), which have good prognosis (Mod Pathol 2011;24:502)
Micro images
=========================================================================
Anus:
Normal anal glands (p63+, fig A/B) and anal gland carcinoma (p63-, fig A)
Bladder or other GU:

Normal urothelium and urothelial carcinoma

Invasive urothelial carcinoma - p63 and beta catenin

Invasive urothelial carcinoma - p63 and Uroplakin III
Bone:
Giant cell tumor
Various - bone tumors
Breast:
Normal
Left-cylindroma, middle-papilloma, right-tubular adenoma
Nipple adenoma - p63 shows intact myoepithelial layer
![]()
Papillary lesions
Collagenous spherulosis versus adenoid cystic carcinoma
DCIS
Left-adenoid cystic carcinoma (solid variant), middle-medullary carcinoma, right-myoepithelial carcinoma
Left-triple negative breast cancer, right-matrix producing carcinoma
Lung (left to right):
Adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma
Lymph nodes:

Benign epithelial inclusions - fig 1: CK5/6+; 2: p63+
Lymphoma:
Left-anaplastic large cell lymphoma is p63+ (fig D) versus right-Reed-Sternberg cells in Hodgkin lymphoma are p63- (fig B)
Maxilla:
Left-nasolabial cyst; right-respiratory epithelial adenomatoid hamartoma (fig 2B, site unspecified)
Nasal septum:
Seromucinous hamartoma is p63 negative (no myoepithelial cells) with positive internal control
Pancreas:
Lymphoepithelial cyst; adenosquamous carcinoma
Prostate:
Biopsies

Nephrogenic adenoma with triple stain mimics adenocarcinoma, with negative staining for p63 and CK903 and positive staining for P504S (red)
Pseudohyperplastic adenocarcinoma - triple stain (p63 stains basal cell nuclei brown, CK903 stains basal cell cytoplasm brown, p504S stains adenocarcinoma cytoplasm red)
Intraductal carcinoma; normal adenocarcinoma versus urothelial carcinoma
Salivary gland:
![]()
Adenoid cystic carcinoma (solid)
Sarcomatoid carcinoma:
Various
Skin:
Primary and metastatic tumors
Left-syringocystadenocarcinoma papilliferum (fig 5); right-sweat gland carcinoma (fig 2B)
![]()
Primary adnexal and metastatic carcinomas
Thyroid:
![]()
Solid cell nests
Uterus:

Endometriosis
Vulva:
![]()
Vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma
Positive staining - normal
=========================================================================
● Breast: myoepithelium (Am J Surg Pathol 2001;25:1054), Toker cells
● Gynecologic tract: basal and parabasal cells of mature
cervical, vaginal and vulval squamous epithelium; cervical reserve cells
at transformation zone, immature metaplastic and atrophic cervical
squamous epithelium (Adv Anat Pathol 20
09;16:316)
● Lung: bronchial reserve cells; metaplastic squamous bronchial epithelium (lower strata)
● Also prostate (basal cells), skin (basal cells), thymus (epithelial cells), urothelium
Positive staining - disease
=========================================================================
● Adenoid cystic carcinoma: but not cases with basaloid growth pattern (Mod Pathol 2005;18:1277)
● Alveolar rhabdomyosarcoma: p63 cytoplasmic staining of Z-bands of skeletal muscle (Mod Pathol 2011;24:1320)
● Bladder: invasive urothelial carcinoma (87%, Am J Surg Pathol 2007;31:673), lymphoepithelioma-like carcinoma (53%, Am J Surg Pathol 2011;35:474)
● Bone: aneurysmal bone cyst (63%), chondroblastoma (83%), giant
cell reparative granuloma (100%), giant cell tumor (87%), nonossifying
fibroma (17%), osteosarcoma (50%), pigmented villonodular synovitis
(25%), tenosynovial giant cell tumor (7%, Arch Pathol Lab Med 2011;135:776)
● Breast: adenoid cystic carcinoma, collagenous spherulosis (Mod Pathol 2006;19:1351), cylindroma, medullary carcinoma, metaplastic carcinoma (Am J Surg Pathol 2008;32:345), myoepithelioma, nipple adenoma, tubular carcinoma; discontinuous staining in LCIS and DCIS (Am J Surg Pathol 2001;25:1054)
● Cervix: epithelioid trophoblastic tumor, lymphoepithelioma-like carcinoma, placental site nodule, spindle cell carcinoma
● Heart: cystic tumor of the atrioventricular node (Am J Clin Pathol 2005;123:369)
● Jaw: nasolabial cyst (Arch Pathol Lab Med 2011;135:1499), sclerosing odontogenic carcinoma (Am J Surg Pathol 2008;32:1613)
● Lymphoma: anaplastic large cell lymphoma (44%) versus 0% for Hodgkin lymphoma (Hum Pathol 2008;39:1505)
● Neuroendocrine carcinoma: variable staining, may be focal / weak (Hum Pathol 2008;39:591)
● Prostate: basal cell hyperplasia (Hum Pathol 2005;36:480), high grade PIN, adenoid basal cell tumor
● Salivary gland: benign or malignant tumors (Hum Pathol 2005;36:821), staining of basal and myoepithelial cells; diffuse staining in oncocytic mucoepidermoid carcinoma (Am J Surg Pathol 2009;33:409)
● Sarcomatoid carcinoma: Mod Pathol 2005;18:1471
● Squamous cell carcinoma and squamous component of adenosquamous carcinoma: Hum Pathol 2001;32:479 - Cervix, Hum Pathol 2002;33:921 - Lung, Am J Clin Pathol 2001;116:823 - poorly differentiated/undifferentiated tumors from various sites
● Thymus: hyperplasia and thymoma (Am J Clin Pathol 2009;131:689), thymic carcinoma (Am J Surg Pathol 2009;33:1113)
● Thyroid gland: CASTLE, Hashimoto's thyroiditis, papillary carcinoma (Hum Pathol 2003;34:764), sclerosing mucoepidermoid carcinoma with eosinophilia, solid cell nests (Mod Pathol 2003;16:43)
● Uterus: endometriosis of peritoneal wall (nuclear staining in
glandular component), but rectovaginal/abdominal wall endometriosis is
p63- (Arch Pathol Lab Med 2007;131:1099), epithelioid trophoblastic tumor (Arch Pathol Lab Med 2006;130:1875)
Negative staining
=========================================================================
● Anus: anal gland carcinoma (Arch Pathol Lab Med 2007;131:1304), but anal squamous cell carcinoma is usually p63+ (Am J Surg Pathol 2007;31:285)
● Breast: normal epithelium, stromal cells, myofibroblasts; may be reduced or occasionally absent in benign apocrine lesions (Am J Surg Pathol 2011;35:202), benign sclerosing lesions (Am J Surg Pathol 2010;34:896) or microglandular adenosis (Am J Surg Pathol 2009;33:496); invasive ductal adenocarcinoma (usually)
● Cervix: glassy cell carcinoma
● Melanoma: Am J Clin Pathol 2008;130:213
● Mesothelioma
● Prostate: adenocarcinoma, nephrogenic adenoma, partial atrophy (Am J Surg Pathol 2008;32:851)
● Most soft tissue tumors (Am J Clin Pathol 2011;136:762)
● Many glandular tumors are negative/weak
End of Stains > p63
This information is intended for physicians and related personnel, who
understand that medical information is often imperfect, and must be
interpreted in the context of a patient's clinical data using reasonable
medical judgment. This website should not be used as a substitute for
the advice of a licensed physician.
All information on this website is protected by copyright of
PathologyOutlines.com, Inc. Information from third parties may also be
protected by copyright. Please contact us at copyrightPathOut@gmail.com
with any questions (click here for other
contact information).